Vaccine composition and application thereof
A technology of vaccine composition and mixture, which is applied in the direction of drug combination, medical preparations containing active ingredients, peptide/protein components, etc., and can solve problems such as poor immune effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0079] Example 1 Expression, identification and purification of Mycoplasma hyopneumoniae protein
[0080] 1.1 Construction of P46 recombinant vector and protein expression, identification and purification
[0081] According to NCBI ( http: / / www.ncbi.nlm.nih.gov ) of the P46 protein nucleotide sequence (see SEQ ID No.1, SEQ ID No.3) in the Mycoplasma hyopneumoniae J strain (Accession No.: AE017243.1) reported in ), the primers and site-specific design of the P46 protein were designed with Primer Premier5 software For the sequence of primers for mutation, see Table 1 for details.
[0082] Table 1P46 protein primer sequence list
[0083]
[0084] According to the method established by Ma Fengying (Ma Fengying, Yao Ruiyu, Zou Haoyong, etc.. Immune response to subunit vaccine of Mycoplasma swine pneumonia. Chinese Journal of Veterinary Medicine, 2012,32(4):529-533), the P46 prokaryotic expression vector was constructed and transformed into the large intestine bacilli express...
Embodiment 2
[0109] The preparation of embodiment 2 swine mycoplasma pneumonia vaccine composition
[0110] The Mycoplasma hyopneumoniae protein prepared in Example 1 is diluted with pH7.2PBS solution, and each protein solution after dilution is mixed with Montanide TM The Gel01 adjuvant is mixed together by the components and ratios contained in the Mycoplasma pneumoniae vaccine composition in Table 3, stirred at a speed of 500-800r / min for 10-15min, and adding 1% (volume ratio) thimerosal solution before terminating the stirring, Make the final concentration not more than 1 / 10,000, shake and mix thoroughly, and store at 2-8°C after aliquoting for later use.
[0111] Table 3 Components and ratios contained in the swine mycoplasma pneumonia vaccine composition
[0112]
[0113] Note: The P36 protein in vaccine I refers to the literature by Hu Maozhi et al. (Hu Maozhi, Jiao Xinan, Zhang Xiaorong, etc. Cloning and expression of the P36 gene specific for Mycoplasma hyopneumoniae. Chinese ...
Embodiment 3
[0114] The efficacy test of the swine mycoplasma pneumonia vaccine composition of different components of embodiment 3
[0115] The vaccine composition prepared in Example 2 was used to immunize 60 piglets at the age of 14-21 days (excluding porcine reproductive and respiratory syndrome, porcine circular type 2 and swine fever), a total of 12 groups, 5 piglets / group, 2mL / head, and set J strain reference vaccine control at the same time. 14 days after the first immunization, the second immunization was carried out according to the same dose and route. On the 28th day after the second immunization, all pigs were injected with virulent Mycoplasma hyopneumoniae Jinan strain CVCC354 into the trachea, 100 MID50 / head, and then dissected after 28 days of observation, and the lung lesions were observed According to the 28-point method, lung lesions were scored. Before and after the challenge, the piglets in the experimental group were weighed, and the average daily gain was calculated...
PUM
| Property | Measurement | Unit |
|---|---|---|
| weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More